Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma

<div>Kaplan–Meier curve survival. OS-curves for (a) patients with synchronous metastatic disease, (b) patients with primary ESFT without metastases, and (c) all patients (<i>n</i> = 64).</div>

Sarcoma

fig5

Figure 5

Figure 5: Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 

Figure 5 | Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 